Breakthrough Discovery In The Battle Against The Herpes Simplex Virus

1. Breakthrough Discovery In The Battle Against The Herpes Simplex Virus According to the US Centre for Disease Control and Prevention, there are around 750,000 cases of herpes reported every year. More than 50 percent of population of the US has Herpes Simplex Virus Type 1. It has become one of the most common viruses that especially poses a risk to pregnant women and new born babies. It wasn’t until very recently that medical advancements were made and the anti-viral vaccine was created. Even though clinical trials were initiated by many medical institutions, they never went past the initial testing phase. Even the Rational vaccines are under investigation by the FDA because they pose a risk to the wellbeing of patients. Such conditions allow for the perception of herpes being an incurable infection to spread and become widely believed. It wasn’t until the study by Synergy Pharmaceuticalsthat people’s frame of mind evolved with the introduction of natural medicine. The study involved the use of using specific T cells that are generated through an Amino Acid formula which is part of the Five Core Compounds (5CC) –Rhodiola, Tribulus, Astragalus and Lysine. The use of these cells has yielded positive results in around 72 percent of the cases that were treated. What is its aim? The study revolves around providing an alternative method of treatment for herpes that involves the use of immunotherapeutic aspects that help curtail the virus inside the body. This treatments prevents the spread of the infection on a cellular level by supressing the activity and building up the immunity of cell membranes. Patients that has a higher concentration of antibodies were selected for a 6 month long treatment in which their infection rates would be constantly monitored. Those who were living with the infection for longer periods of time had higher levels of lgG antibodies which is how the efficacy of the study was determined –through regular and proper observation. There was an additional criteria created in order to improve the quality of the results achieved. No patient that has received treatment in the last 2 months, lactating, pregnant, low immunity and allergic were allowed to be part of the study.

2. Who was the study carried out by? The Study was carried out by Bernard Middleton and Susan Cosgrove –both scientists who aim to improve the medical field. Bernard Middleton is an expert in virology and gained valuable experience catering to patients in hospitals across Australia. His experience and understanding of viruses coupled with Susan Cosgrove’s evaluative mindset has created a new path of treatment for herpes that functions like alternative treatments. How was the study carried out? According to the Singapore Virology Conference, 5CC has been targeted at Herpes Simplex Virus Type 1 and Type 2 at various stages of the infection; the entry stage, reproductive cross mutation and its spread from one cell to the other. 5CC would neutralize the monoclonal antibodies thus causing the infection to completely dissolve. According to the study, ‘5CC combinations of inhibitors of Herpes virus DNA synthesis and interferon (IFN)-induced cellular antiviral response neutralized against viral reproduction by blocking cell to cell infection.’ The study put a light on the suppressant nature of 5CC after being tested on RC-37 cells through a plaque reduction assay. The study states that, ‘The 50% inhibitory concentration (IC50) of 5CC for herpes simplex virus plaque formation was 0.0009% and 0.0008%.’ The plaque formation was reported to have been reduced by 98.2 to 93 percent in total. The study, since it involved the use of a method of treatment on patients, was regulated by the University Medical Review Board and a written consent was filed by every participant. What are the results? The results have been looking promising because of the fact that they validate the claim that 5CC can actually become a successful way to treat herpes. It eliminates the infection through treating each and every cell. This is exactly what causes the plaque formation to remain within the boundaries of 0.0009–0.008 percent.

3. When the individual components of 5CC were used separately, they did not display this extend of positive results. This naturally occurring combination has been shown to promote a conducive environment in the body all the while allowing for the creation of an anti-herpetic drug. Instead of vaccines or medicines, this course of treatment has the potential to be easily accessible and successful because of how effective it is. What comes next? Synergy Pharmaceuticals expanded their study and utilized the 5CC as a method of treatment for the public. Despite the fact that it can diminish the infection and fight of remaining antibodies, there has been little to no progress when it comes to building immunity. Thus, once you have already suffered from herpes, you can get the infection again. While a solution has been created, this study could also open the door to more projects and research that will focus on the preventative measures like creating an immunity shot. When dealing with viruses, anti-viral injections and medicines have taken over the pharmaceutical industry because they prevent people from catching them. For further information visit http://www.treatment4herpes.com